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ILLUSTRATIVE CASE
Is there anything you can do for this 
patient? A 25-year-old man with newly 
diagnosed schizophrenia and a baseline 
weight of 175 pounds comes to see you 
because he has gained 18 pounds in the 
fi rst 6 months after starting olanzapine. 
Concerned because his mother has 
diabetes, he asks if you can help him lose 
weight safely. You make your usual recom-
mendation that he increase his daily physi-
cal activity (including buying a pedometer, 
setting a daily step goal, and keeping a 
log)2 and decrease his total caloric intake, 
but you know the chances of success are 
not great. What about a weight loss medi-
cation? Might that improve the odds?
Metformin might improve the odds. This study gives us an additional tool for treating 
antipsychotic-induced weight gain. This 
is useful information, because most sec-
ond-generation (or atypical) antipsy-
chotic medications cause weight gain. 
Weight gain can lead to decreased ad-
herence to treatment and, therefore, in-
creased risk of psychotic relapse in ad-
dition to the increased risk of diabetes 
and cardiovascular disease associated 
with weight gain. 
Antipsychotics exhibit variability 
in the amount of weight gain and risk 
for diabetes they cause (TABLE 1). Olan-
zapine and clozapine defi nitely increase 
the risk for diabetes. The association of 
diabetes with risperidone and quetiapine 
is uncertain, and early experience with 
aripiprazole and ziprasidone does not 
indicate an increased risk of diabetes.3,4
The prevalence of obesity and diabe-
tes among people with schizophrenia and 
affective disorders is 1.5 to 2 times higher 
than in the general population. This dif-
Recommend metformin 250 
mg 3 times a day, along with 
lifestyle modifi cations, to pro-
mote weight loss and decrease 
insulin resistance in patients 
who gain more than 10% of 
their pretreatment body weight 
on antipsychotic medications.
Strength of recommendation 
B: Based on a single, well-designed, randomized 
controlled trial.
Wu R-R, Zhao J-P, Jin H, et al. Lifestyle interven-
tion and metformin for treatment of antipsychotic-
induced weight gain: a randomized controlled 
trial. JAMA. 2008;299:185-193.1
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Can metformin undo weight gain
induced by antipsychotics?
Convincing evidence shows that metformin alone 
and in combination with lifestyle changes is superior 
to lifestyle changes alone or placebo 
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PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
ference is likely due to a combination of 
sedentary behavior and the use of sec-
ond-generation antipsychotics. Obesity 
and diabetes are risk factors for cardio-
vascular disease, and the relative risk of 
mortality from cardiovascular disease is 
signifi cantly higher among people with 
psychiatric disorders than in the general 
population.3 More than two thirds of pa-
tients with schizophrenia die of coronary 
heart disease, compared with about 50% 
of the general population.4
❚  Lack of evidence 
for weight loss drugs
The most recent guideline on this topic 
does not recommend any medication, cit-
ing a lack of evidence. In its 2003 consen-
sus statement, a panel representing the 
American Diabetes Association, Ameri-
can Psychiatric Association, American 
Association of Clinical Endocrinologists, 
and the North American Association for 
the Study of Obesity3 recommends:
• That patients taking second-gen-
eration antipsychotics have the following 
assessments at baseline and regular inter-
vals: weight, height, waist circumference, 
blood pressure, fasting plasma glucose, 
and fasting lipids. 
• Providing nutrition and exercise 
counseling to all patients who are over-
weight or obese at baseline. 
• Initiating treatment with one of the 
second-generation antipsychotics with a 
lower risk of weight gain for patients at 
high risk of diabetes (ie, family history) 
and for patients who gain 5% or more of 
their initial weight or develop worsening 
hyperglycemia or dyslipidemia during 
treatment. 
This guideline does not recommend 
metformin to reduce weight gain.
A 2007 Cochrane review of interven-
tions to reduce weight gain in patients 
with schizophrenia included 23 random-
ized controlled trials of a variety of weight 
loss interventions, including cognitive/be-
havioral interventions and a variety of 
medications, including sibutramine, orli-
stat, fl uoxetine, topiramate, and metfor-
min. The authors highlighted the limited 
number of studies of short duration and 
with small sample sizes and concluded 
that the evidence was insuffi cient for the 
use of pharmacologic interventions to 
prevent or treat weight gain.5
STUDY SUMMARY
❚  Lifestyle changes and 
metformin compared
This randomized controlled trial was 
conducted in China and included 128 
adults aged 18 to 45 with a fi rst psychot-
ic episode of schizophrenia. All patients 
had to have gained more than 10% of 
their pretreatment body weight during 
the fi rst year of treatment with an anti-
psychotic medication (clozapine, olan-
zapine, risperidone, or sulpiride [not ap-
proved for use in the United States]). All 
study participants had to be under the 
care of an adult caregiver who monitored 
and recorded food intake, exercise, and 
medication intake. Patients with diabetes, 
cardiovascular disease, liver or renal dys-
function, substance abuse, or psychiatric 
diagnoses other than schizophrenia were 
excluded.
Patients were randomized to 1 of 
4 groups for the 12 weeks of the study: 
• Metformin alone, 250 mg 3 times daily 
• Placebo alone 
• Lifestyle intervention plus metformin
• Lifestyle intervention plus placebo 
More than 
two thirds 
of patients with 
schizophrenia die 
of coronary heart 
disease
Risk of weight gain and diabetes 
with atypical antipsychotic medications3,4
MEDICATION 
(TRADE NAME)
RISK OF SIGNIFICANT 
WEIGHT GAIN
RISK FOR 
DIABETES
Clozapine (Clozaril) +++ +
Olanzapine (Zyprexa) +++ +
Quetiapine (Seroquel) ++ ? (discrepant results)
Risperidone (Risperdal) ++ ?
Ziprasidone (Geodon) +/– –
Aripiprazole (Abilify) +/– –
TABLE 1
C O N T I N U E D
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The lifestyle intervention included 3 
components: (1) education: monthly pro-
grams on nutrition and physical activity; 
(2) diet: the American Heart Association 
step 2 diet (<30% calories from fat, 55% 
carbohydrates, >15% protein, with at 
least 15 g fi ber per 1000 kcal); and (3) 
exercise: 1 week of sessions with an exer-
cise physiologist followed by an individu-
alized home-based exercise program.
Primary outcomes included chang-
es in weight, body mass index (BMI), 
waist circumference, and fasting glucose 
(TABLE 2). Ten of the 128 randomized pa-
tients either discontinued the study or 
were lost to follow up, but all 128 pa-
tients were included in the analysis.
❚  Best result: Lifestyle 
changes plus metformin
Compared with baseline, weight de-
creased by 7.3% in the lifestyle plus met-
formin group, by 4.9% in the metformin-
only group, and by 2.2% in the lifestyle-
only group; in the placebo group, weight 
increased by 4.8%. 
Participants in all 3 intervention 
groups also showed signifi cant decreases 
in the mean fasting glucose, insulin levels, 
and insulin resistance index (IRI). The in-
sulin levels and the IRI increased in the 
placebo group.
No signiﬁ cant differences in adverse 
effects were noted among the 4 treat-
ment groups.1
WHAT’S NEW
❚  Convincing evidence
This is the fi rst randomized controlled trial 
to show convincingly that metformin alone 
or in combination with lifestyle changes is 
superior to lifestyle changes alone or pla-
cebo for reducing weight gain and other 
adverse metabolic outcomes induced by 
second-generation antipsychotics.
Intensive lifestyle interventions
Prior studies found that intensive lifestyle 
interventions can help reduce antipsychot-
ic-related weight gain. A 3-month random-
ized controlled trial compared an early be-
havioral intervention (dietary counseling, 
an exercise program, and behavior thera-
py) with routine care in 61 patients with 
fi rst-episode psychosis who were taking 
risperidone, olanzapine, or haloperidol;6 
signifi cantly fewer patients assigned to be-
havioral intervention had an increased ini-
tial body weight of more than 7%: 39% in 
the behavioral intervention group vs 79% 
in the routine care group (P<.002).
Small samples, small effect sizes
Past studies of metformin for antipsy-
chotic-associated weight gain have gen-
erally shown a small benefi t, though 
small sample sizes and small effect sizes 
prohibited defi nitive conclusions. Unlike 
the study by Wu and colleagues,1 none 
of these past studies were designed to 
compare the combination of metformin 
and lifestyle intervention with metfor-
Before adding 
metformin for 
weight loss, 
contact the 
psychiatrist 
and discuss other 
antipsychotic drug 
options
Mean difference between baseline and 
endpoint (week 12) of treatment outcomes 
(95% confi dence intervals)1
LIFESTYLE + 
METFORMIN METFORMIN LIFESTYLE PLACEBO
Weight, kg -4.7 (-5.7 to -3.4) -3.2 (-3.9 to -2.5) -1.4 (-2.0 to -0.7) 3.1 (2.4 to 3.8)
BMI, kg/m2 -1.8 (-2.3 to -1.3) -1.2 (-1.5 to -0.9) -0.5 (-0.8 to -0.3) 1.2 (0.9 to 1.5)
Waist circumference, cm -2.0 (-2.4 to -1.5) -1.3 (-1.5 to -1.1) 0.1 (-0.5 to 0.7) 2.2 (1.7 to 2.8)
Fasting glucose, mg/dL -7.2 (-10.8 to -5.4)
-10.8 
(-16.2 to -7.2)
-7.2 (-9.0 to -3.6) 1.8 (-1.8 to 3.6)
TABLE 2
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Can metformin undo antipsychotic-induced weight gain? 
min alone, lifestyle intervention alone, or 
placebo alone. 
Klein et al conducted a randomized 
placebo-controlled trial of metformin in 
39 children ages 10 to 17 whose weight 
had increased more than 10% on atypi-
cal antipsychotic therapy.7 The children 
treated with placebo gained a mean of 4 
kg and increased their mean BMI by 1.12 
kg/m2 during 16 weeks of treatment, 
while those in the metformin group did 
not gain weight and decreased their mean 
BMI by 0.43 kg/m2.
Baptista et al randomized 40 in-
patients with schizophrenia, who were 
being switched from conventional anti-
psychotics to olanzapine, to either met-
formin (850-1750 mg/d) or placebo. 
Both groups gained a similar amount of 
weight after the 14-week study (5.5 vs 6.3 
kg, metformin vs placebo). Three patients 
who started with high fasting glucose had 
decreases while taking metformin, and 3 
patients given placebo developed elevated 
fasting glucose during the study.8
In another randomized controlled 
trial of metformin vs placebo in 80 pa-
tients who had been taking olanzapine 
for at least 4 months, Baptista et al found 
only a small, insignifi cant difference in 
weight loss after 12 weeks of treatment 
(metformin group lost 1.4 kg, placebo 
group lost 0.18 kg, P=.09). They reported 
that both groups were highly motivated 
to lose weight and were compliant with 
the healthy lifestyle recommendations.9
An adequately powered study
The trial1 highlighted in this PURL had 
an adequate sample size to compare 
metformin plus a lifestyle intervention 
with either treatment alone or placebo. 
It showed a clinically important effect of 
metformin both by itself and in conjunc-
tion with the lifestyle intervention.
CAVEATS
❚  Consider switching drugs 
Before adding metformin to help with 
weight loss, primary care clinicians should 
contact the patient’s psychiatrist to dis-
cuss the option of switching antipsychotic 
medications. Switching from a medication 
with a higher risk for weight gain, such as 
olanzapine, to one with a lower risk, such 
as aripiprazole or ziprasidone, can lead to 
signifi cant weight loss.10 
Not an option for some
However, some patients, especially those 
taking clozapine, may have already tried 
multiple antipsychotic agents without 
success, and switching is not an option 
for them.
❚  Prescribing metformin
Contraindications
Metformin should not be prescribed to 
patients with serum creatinine concen-
trations of more than 1.5 mg/dL or those 
with unstable heart failure, due to the 
risk of lactic acidosis.
Dosing
The dose of metformin used in this study 
was 250 mg 3 times daily. The other stud-
ies cited used higher doses, ranging from 
850 to 2550 mg daily. We recommend 
starting with a lower dose and increasing 
the dose as needed to achieve a therapeu-
tic effect.
Duration of treatment
This trial was only 12 weeks in dura-
tion and does not give us evidence on 
long-term maintenance, so the decision 
about continuation will need to be 
individualized based on clinical judg-
ment. If the patient loses weight, we 
think that either continuing the met-
formin or giving the patient a trial off 
of it (and restarting if the patient re-
gains weight), would both be reason-
able strategies.
Is this study applicable in the US?
This study was conducted in China, 
which raises the question of generaliz-
ability. We can think of no biological rea-
son why these results may not apply to 
US patient populations.
Advise patients 
that possible 
GI side effects 
of metformin 
tend to lessen 
or disappear 
with time
C O N T I N U E D
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CHALLENGES TO IMPLEMENTATION
❚ Adherence
These study participants were under the 
care of an adult caregiver who monitored 
and recorded food and medication intake 
and exercise level. The lifestyle interven-
tion was thorough and structured and 
this kind of program is often not available 
to us for our patients. As a consequence, 
we may not obtain the same results as in 
this study. However, even the metformin-
alone group showed improvements, and 
if our patients can reliably take their sec-
ond-generation antipsychotic, they should 
also be able to take metformin reliably.
❚ Patient resistance
Some patients may resist taking an addi-
tional medication to treat the side effects 
of their antipsychotic medication. Tak-
ing the time to educate them about the 
increased risk of diabetes and cardiovas-
cular disease related to weight gain may 
help convince them to do so. Warn them 
about possible gastrointestinal adverse 
effects of metformin, which tend to lessen 
or disappear with time. ■
The PURLs Surveillance System is supported in part by 
Grant Number UL1RR024999 from the National Center 
For Research Resources, a Clinical Translational Science 
Award to the University of Chicago. The content is solely 
the responsibility of the authors and does not necessarily 
represent the offi cial views of the National Center For Re-
search Resources or the National Institutes of Health. 
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